On Aug. 10, the U.S. Food and Drug Administration (FDA) approved Lucentis (ranibizumab injection) for the treatment of diabetic macular edema. Read more.
On July 17, the U.S. Food and Drug Administration (FDA) approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie diet and…
On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm in patients…
On June 8, the U.S. Food and Drug Administration (FDA) approved Perjeta (pertuzumab), a new anti-HER2 therapy, to treat patients with HER2-positive late-stage breast…
On May 30, the U. S. Food and Drug Administration (FDA), National Institute for Occupational Safety and Health (NIOSH), and Occupational Safety and Health…
On May 29, the U.S. Food and Drug Administration (FDA) warned consumers and healthcare professionals about a counterfeit version of Teva Pharmaceutical Industries’ Adderall…
On April 27, the U.S. Food and Drug Administration approved Levaquin (levofloxacin) to treat patients with plague. The drug was approved under the agency’s…
The U.S. Food and Drug Administration has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF) products. This…
On July 17, the U.S. Food and Drug Administration (FDA) approved Qsymia (phentermine and topiramate extended-release) as an addition to a reduced-calorie…
On July 23, the U.S. Food and Drug Administration (FDA) approved Tudorza Pressair (aclidinium bromide) for the long-term maintenance treatment of bronchospasm…
On May 29, the U.S. Food and Drug Administration (FDA) warned consumers and healthcare professionals about a counterfeit version of Teva Pharmaceutical…
The U.S. Food and Drug Administration has approved a single shared Risk Evaluation and Mitigation Strategy (REMS) for transmucosal immediate-release fentanyl (TIRF)…